Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205954 · ClinicalTrials.gov registry record · NA
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
A NA study of Cirrhosis and End Stage Liver DIsease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05205954: Recruiting NA study of Cirrhosis and End Stage Liver DIsease, sponsored by Massachusetts General Hospital.
NCT05205954 is a NA study of Cirrhosis and End Stage Liver DIsease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05205954, a NA study of Cirrhosis and End Stage Liver DIsease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
Primary Outcome
The intervention will be deemed feasible if less than 20% of enrolled patients have escalation of care back to the inpatient (brick-and-mortar) hospital
Conditions Studied
Interventions
- BEHAVIORAL Hepatology Home Hospital
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05205954 shows while recruiting
NCT05205954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Hepatology Home Hospital is the first listed.
NCT05205954 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05205954 about?
NCT05205954 is a clinical study titled "HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease". This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
What is the current status of trial NCT05205954?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-07-21. Estimated completion is 2026-12-31.
What conditions does trial NCT05205954 study?
This clinical trial studies the following conditions: Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic.
What interventions are being tested in trial NCT05205954?
The interventions under investigation include: Hepatology Home Hospital (BEHAVIORAL).
Who is sponsoring clinical trial NCT05205954?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05205954 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05205954's enrollment target sits among peer trials
30 31st of 53 higher than 13 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI